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Abstract. The prostate transglutaminase, TGase-4, is a
member of the transglutaminase family and is uniquely
expressed in the prostate gland. The function of the protein is
largely unknown, although an influence on cell motility and
adhesion has been indicated. The present study investigated
the impact of the differential expression of TGase-4 in human
prostate cancer cells on RON, the hepatocyte growth factor-
like/macrophage-stimulating protein (HGF-L/MSP) receptor,
mediated cellular functions. Using human prostate cancer cell
lines and prostate tissues, we demonstrated that human TGase-4
had a high degree of co-localisation with RON, primarily at
the cell periphery and cell-cell adhesion region. High levels
of TGase-4 expression in CAHPV10 cells and in PC3 cells
engineered to over-express TGase-4 were associated with
significantly increased cell motility in response to HGF-L, a
clear contrast to wild-type and control cells. Neutralising
antibody to RON and rhHGFL/MSP had no further bearing
on the increased motility in TGase-4 over-expressing cells,
although they had profound effect on the control cells. Akt
pathway inhibitor significantly diminished the effect induced
by HGF-L in the cells. Finally, over-expression of TGase-4 in
prostate cancer cells resulted in autophosphorylation of RON.
It is concluded that TGase-4 expression is intrinsically linked
to the activation of RON in prostate cancer cells and that this
autoactivation of RON contributes to the increased cell motility
in TGase-4 expressing cells.
Introduction
Transglutaminases [EC 2.3.2.13 (TGases)] are a family of
proteins that catalyse the post-translational modification of
proteins by the formation of Â-(Á-glutamyl) lysine isopeptide
bonds. One of the unique TGases is the prostate transglu-
taminase (also known as TGase-4 or TGaseP). TGase-4 is
largely confined to the prostate gland (1-3). TGases were
implicated as contributory to the early suggested concept
and role of the tumour microenvironment and tumorigenesis
(4-7), regulate the adhesion to matrix and migration over
matrix (8,9). These controversial in vitro reports are reflected
by clinical observations that TGase-2 has been shown to be
either favorably or inversely correlated with patients outcome
(10).
There is little knowledge on the role of TGase-4 in cancer.
Restricted to luminal epithelial cells (with no presence in basal
epithelial cells or stromal cells), TGase-4 protein was
observed in high-grade prostate intraepithelial neoplasia.
TGase-4 was seen at a lower level in prostate cancer compared
with normal tissues. Metastatic prostate tumours also showed
lost of expression (11). The expression pattern of TGase-4 has
not been found thus far for any other prostate-specific marker
(12). Discovered from a human prostate cDNA library (2), the
679 AA transglutaminase was found to share homology with
human endothelial cell TGase (88%) and rat prostate TGase
(51%). In a recent study (13), we found the expression pattern
of TGase-4 in cells from different tissue origin is broader than
we initially anticipated. Colon cancer, lung cancer and prostate
cancer cell lines have varying degrees of expression of the
enzyme. This is an interesting observation, as previous studies
have used normal human tissue cDNAs (1,12,14). This
indicates that the expression of TGase-4 may vary between
the normal cells and the more genetic instable cancer cell
counterpart. The function of the prostate TGase is far from
clear. The rat homologue, rat prostate TGase (or DP1) has been
suggested to be involved to some degree in sperm cell motility
and immunogenicity (15,16) and immunoregulation (4,5). Our
recent study (13) demonstrated that loss of TGase-4 from
CAHPV10 cells resulted in the cells being less invasive with or
without stimulation by hepatocyte growth factor. Furthermore,
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TGase-4 has also been shown to influence the interaction
between prostate cancer cells and endothelial cells (17).
Together with the report that TGase can be up-regulated by
androgen in PC346C, but not in LNCaP cells (despite both
being androgen responsive cell lines) (1), this suggests that the
enzyme may play a role in the control of invasiveness.
RON belongs to a small receptor-type protein tyrosine
kinase family and is the receptor for the HGF-like protein
(HGF-L, also known as MSP). RON is comprised of two
subunits, joined by disulfide bonds with the ß subunit being
the main functional unit of the receptor. Upon stimulation by
HGF-L, two main clusters of tyrosine sites on the intracellular
domain are activated/phosphorylated, Y1238/Y1239 site - the
main catalytic site and Y1353/Y1360 - the main docking site of
the RON. Downstream of RON activation are a few signalling
pathways which ultimately lead to the specific cellular events,
for example, Src/MAPK pathway for the mitogenic effect,
PI3-K/Akt pathway for the growth/survival and motility effect
elicited by HGF-L/MSP (18,19). In cancer, RON is over-
expressed in breast cancer, colorectal cancer, lung cancer and
kidney cancer (20-22). Furthermore, HGF-L has been shown
to have an increased expression in breast, lung and pancreatic
cancers (21-24). So far, only limited information is available
on RON and HGF-L expression in prostate cancer, in that the
staining of RON total protein in tumour was not different from
that in normal tissues.
In an attempt to decipher the molecular and cellular mecha-
nisms underlying the action of TGase-4, we conducted a series
of protein interaction by way of immunoprecipitation using
proteins from human prostate tissues. One of the interacting
proteins with TGase-4 was RON. The present study examined
how RON and TGase-4 interplayed in the regulation of cellular
functions of prostate cancer cells.
Materials and methods
Materials and cell lines. Human prostate cancer cells, PC-3
and CAHPV10 were from American Type Cell Collection,
Manassas, VI, USA. Fresh frozen prostate tissues were
collected from University Hospital of Wales under the approval
of local ethics committee and obtained immediately after
surgery and stored at -80˚C until use.
Rh-HGF-L/MSP and anti-HGF-L receptor/RON (neutra-
lising and non-neutralising were from R&D Systems. Anti-
RON and an anti-phosphoRON were from Santa Cruz
Biotechnology Inc. Anti-TGase-4 Pab and Mab, respectively
from Covalab, ABCAM, and Abnova. ROCK small inhibitor
(Y27632) was from Santa Cruz Biotechnology Inc. PI-3-K
inhibitor, Akt inhibitor, JNK inhibitor II, ERK inhibitor II, Met
kinase inhibitor, Wiskostatin, JAK-3 inhibitor, Jak-Stat
pathway inhibitor, PLC-Á inhibitor and Stat-5 inhibitor were
from Calbiochem.
Construction of anti-TGAse-4 hammerhead ribozyme
transgenes and TGase-4 expression vector. Hammerhead
ribozymes that specifically target a GTC site of the human
prostate TGase-4 (GenBank accession NM_003241) were
generated as previously described (13,25), using the respective
primers (Table I) and the transgene constructed using a
pEF6/V5-His vector (Invitrogen, Paisley, Scotland, UK). The
following stably transfected cells were established: TGase-4
knock-down cells (CAHPV10ΔTGase4), plasmid only control
cells (CAHPV10pEFa), and the wild-type, CAHPV10wt.
Full length human TGase-4 coding region was amplified
from a cDNA pool of human prostate tissues using primers
listed in Table I. The TGase-4 full length coding product was
similarly cloned into the pEF6 vectors. Stably transfected cells
were designated as PC3pEF/His and PC3TGase4exp, for control
transfection and TGase-4 expression, respectively.
RNA preparation, RT-PCR and quantitative analysis of
TGase-4 transcript. The polymerase chain reaction (PCR) was
performed using sets of primers, given in Table I. ß-actin was
amplified and used as a house-keeping control. The level of
the prostate TGase transcripts in the above-prepared cDNA
was also determined using a real-time quantitative PCR,
based on the Amplifluor™ technology that was modified
from that the previously reported (26). The levels of the
transcripts were generated from an internal standard (27) that
was simultaneously amplified with the samples.
Electric cell-substrate impedance sensing (ECIS) based cell
adhesion assay. Two models of ECIS instrument were used:
ECIS9600 for screening and ECIS1600R for modelling. In
both systems, 8W10 arrays were used (Applied Biophysics
Inc., Troy, NY, USA) (28,29). Following treating the array
surface with a Cysteine solution, the arrays were incubated
with complete medium for 1 h. The same number of prostate
cancer cells, PC3pEF/His, PC3TGase4exp, or PC3wt, CAHPVΔTGase4,
CAHPVpEF/His or CAHPVwt (300,000 per well) were added
to each wells. Electric changes were continuously monitored
for up to 24 h. In the 9600 system, the monitoring was fixed
at 30 Hz. In the 1600R system, two conditions were
recorded: 400, 4,000 and 40,000 Hz for screening the nature
of changes and 4,000 Hz fix frequency for cell modelling
(30).
Detection of RON/HGFLR activation using Western blotting.
Prostate cancer cells were subject to serum before being
treated with either plain medium, rhHGFL/MSP or sodium
orthovanadate (10 μM in the presence of 1% H2O2, as positive
control). The proteins were loaded onto 8% SDS-PAGE.
Following blotting, the membranes were first blocked by 10%
semi-skimmed milk before probing with anti-RON or anti-
phosphoRON (Tyr1238/1239) antibody. After being processed
in enhanced chemiluminescent solution, images were obtained
using the LumiDoc imaging system (UniDoc, Cambridge,
UK).
Immunofluorescence staining of TGase-4 and the HGF-L
receptor, RON in cells and tissues. Fresh prostate tissues
(normal and tumour) were collected immediately after radical
prostectomy. Frozen sections of prostate tissues (normal and
tumour) were cut at a thickness of 6 μm using a cryostat. Fixed
sections were incubated in a blocking solution and probed
with the primary antibodies, followed by the secondary FITC-
and TRITC-conjugated in the presence of Hoechst 33258 at
10 μg/ml (Sigma, St. Louis, MO, USA), separated by extensive
washings. The images were documented using Cell Lysis
software (Olympus).
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Statistical analysis was carried out using Minitab. For
normality test Anderson-Darling test and for statistical
difference Student's t-test were used.
Results
TGase-4 co-localises with RON in CAHPV10 prostate cancer
cells, cells highly expressing TGase-4. To test if there is a
spatial relationship between TGase-4 and RON, we selected
CAHPV10 cells, a cell type that was shown to highly express
TGase-4 in comparison with other prostate cancer cells. Using
dual immunofluorescence staining, a clear co-localisation was
seen (Fig. 1A, left). It is noteworthy that the co-localised
TGase-4 and RON are seen at the cell periphery (arrows) and
cell-cell adhesion areas (arrowheads), with degree of intra-
cellular staining. The superimposed images have shown that the
co-localisations occur more prominently at the cell-cell junction
area and cell peripheries. Forced expression of TGase-4 in PC-3
cells (PC3TGase4exp) also resulted in degree of co-localisation of
TGase-4 and RON, primarily at the cell periphery (Fig. 1A,
arrows) and in the cytoplasm region (arrowheads). CAHPV10
cells showing high level expression of TGase-4, were
tranfected with the anti-TGase-4 ribozyme transgene. Cells
which had virtually lost the TGase-4 transcript (CAHPVΔTGase4)
as the result of the transgene, were obtained.
Similar to the CAHPV, PC3TGase4exp which now expressed
good level of TGase-4 following transfection, also showed
co-localised TGase-4 and RON. Co-localisations are seen in
both cell-cell contact areas as well as in the cytoplasmic
regions (indicated by arrows in the merged image) (Fig. 1A,
right panel).
Co-localisation of TGase-4 and RON in human prostate
tissues. Using dual immunofluorescence staining of HGFLR/
RON and TGase-4, we attempted to address if the two proteins
also co-localised in human prostate tissues. As shown in an
example in Fig. 1B, TGase-4 and RON showed a high degree
of co-localisation in the tissues at the locations seen with the
cells. In addition, TGase-4 proteins were seen in both extra-
cellular matrix and in the cytosol in the tissues.
Forced expression of TGase-4 in PC3 cells increases cell
motility, the change is directly affected by RON. Using cells
of which TGase-4 expression was genetically manipulated,
we first tested the impact on the cell motility using a Electric
Cell Impedance Sensing (ECIS) assay. As shown in Fig. 2,
loss of TGase-4 in CAHPV10 cells by way of ribozyme (Fig.
2A) and forced expression of TGase-4 in PC-3 cells (Fig. 2B)
resulted in increased in cell motility, as demonstrated by
rapid rise of resistance (R) after electric wounding.
To test the impact of RON on TGase-4 mediated cell
motility, we used a neutralising antibody to human RON
protein on PC-3 cells, which had good level of expression of
both RON and its ligand HGF-L. Interestingly, anti-RON
blocked the migration of PC-3 control cells after wounding,
however, the impact of anti-RON on PC3TGase4exp cells was very
limited (Fig. 2B). Likewise, we have evidence to show that
neutralising anti-RON was able to reduce the cell adhesion to
the electrode in PC3-control cells and that PC3TGase4exp cells
had lost this response.
Impact of rhHGFL and anti-RON/HGFLR on the motility
of prostate cancer cells. Using ECIS based cell modelling
of cell motility, we showed that recombinant human HGF-
Lfg/MSP significantly increase the motility of control cells
(Fig. 2C). However, PC3TGase4exp cells, the motility of which
was increased, did not shown a significant response to rhHGF-
L/MSP (Fig. 2C). Neutralising anti-RON antibody resulted in
a significant reduction of the motility in control cells, but not
in PC3TGase4exp cells.
RON/HGFLR activation by rhHGFL/MSP and TGase-4 over-
expression. Using a phosphor-specific anti-RON antibody, it
was shown that rhMSP resulted in the phosphorylation of
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Table I. Primer and oligo-sequences used in the study.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Sense (5'-3') Antisense (5'-3')
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
TGase-4 expression Atgatggatgcatcaaaaga Ctacttggtgatgagaacaatcttctga
TGase-4 ribozyme1 Atgatggatgcatcaaaagag Ctacttggtgatgagaacaa
TGase-4 ribozyme1 ctgcagtttggaactcccatgtgtggtgactgatgagtccgtgagga actagttgaatcaggacaacgccgtttttcgtcctcacgga
TGase-4 ribozyme2 ctgcagttcagttggtggtggtagctgatgagtccgtgagga actagtccagcccctacaatttcgtcctcacggga
TGase-4 (position 62) atggatgcatcaaaagagc AggtgaaacacctgtcctcAactgaacctgaccgtacaa
ggtgaaacacctgtcctc, for Q-PCR)
TGase-4 (position 1957) ataaaatgcaccccaataaa Ctacttggtgatgagaacaatc(actgaacctgaccgtacacc
tacttggtgatgagaacaatc, for Q-PCR)
GAPDH agcttgtcatcaatggaaat cttcaccaccttcttgatgt
GAPDH for Q-PCR ctgagtacgtcgtggagtc Actgaacctgaccgtacacagagatgatgacccttttg
ß-actin atgatatcgccgcgctcg cgctcgtgtaggatcttca
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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RON at the tyrosine in both wild-type and in control cells. It
is interesting to note that autophosphorylation of the receptor
was seen in PC3TGase4exp cells, with or without rhHGF-L/MSP
(Fig. 3).
Akt inhibitor had a strong inhibitory effect on MSP-induced
motility. A panel of small inhibitors to certain key pathways
downstream of MSP and RON. Akt inhibitor showed a
significant effect on MSP-induced migration both in PC-3
control and PC3TGase4exp cells (Fig. 4).
Discussion
The present study is the first to demonstrate that TGase-4, a
prostate-specific transglutaminase, acted in orchestration with
the HGF-L/MSP receptor RON in enhancing the motility of
prostate cancer cells. The study further demonstrated that the
TGase-4 induced increase in cell motility is independent of
the presence of the RON ligand, HGFL/MSP.
The transglutaminase family has been indicated in the
regulation of cell motility and cell-matrix adhesion. Recently,
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Figure 1. (A) Co-localisation of TGase-4 and RON/HGFLR in CAHPV10 human prostate cancer cell lines (left and middle panels). The two proteins were seen
to co-localise at periphery and cell-cell adhesion regions of the cells. Right panel, co-localisation of TGase-4 and RON/HGFLR in PC3 cells with forced expression
of TGase-4 (PC3TGase4exp). Both proteins were seen at the periphery and cell-cell adhesion regions. (B) Co-localisation of TGase-4 and RON/HGFLR in human
prostate tissues. HOE, nucleus constained with Hoechst 33258. Comp., superimposed images.
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we have shown that knocking down the expression of TGase-
4 from a human prostate cancer cell lines, CAHPV which
naturally expressed TGase-4, resulted in less motility and
adhesive cells (13), an observation leading to suggestion that
TGase-4 is also a motility regulator in prostate cancer cells.
Motility of cells is regulated by a number of extracellular
regulators. It has been well documented that HGF/SF acts via
its receptor, cMET, and contributed to the aggressive nature
of cancer cells. The present study was the direct result of a
proteomic based study in our laboratory in which we found
that RON is one of the small number of proteins interacting
with TGase-4. In the present study, the spatial co-localisation
between TGase-4 and RON has been confirmed in both
prostate cancer cells and in prostate tissues. This is important
when considering the potential impact of TGase-4 expression
on RON activation and on HGFL/MSP-induced cell motility in
prostate cancer cells. First, it is clear that prostate cancer cells
over-express TGase-4, i.e., PC3TGase4exp autophosphorylates
RON, in the absence of exogenous HGFL/MSP. This
indicates that TGase-4 by either a direct or an indirect
mechanism, resulted in the activation of the RON kinase.
Second, TGase-4 expressing cells with RON activation
displayed increase in cell motility, independent of
HGFL/MSP and that neutralising antibody to RON had no
impact on the increased motility of the cells. Collectively,
acquisition of TGase-4 expression in prostate cancer cells
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Figure 2. (A) Differential expression of TGase-4 rendered cells with different motility. Knocking down of TGase-4 from CAHPV10 of TGase-4 in PC-3 cells
enabled cells to increase migration. (B and C) Effect of rhHGFL/MSP and the neutralising anti-RON antibody on the migration of PC-3 cells. *p<0.05 vs
control; **p<0.05 vs with HGF-L only.
Figure 3. Effect of rhHGFL/MSP and TGase-4 over-expression on the
autophosphylation of RON in PC-3 cells. L, total cell lysate.
Figure 4. TGase-4 expression and effect of Akt and PI3K pathway inhibitors
on the motility of PC-3 cells, determined using the ECIS cell model and
analysed by Rb cell modelling. Resistance is shown. MSP used was 40 ng/ml.
Akt inhibitor, 200 nm; PI3K inhibitor (wortmannin), 200 nm. *p<0.05 vs the
respective non-inhibitor control; **p<0.05 vs the respective PC3wt control.
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enabled the cells to have auto-activated RON, which in turn
elicits the activation mechanism for cell motility.
HGFL/MSP-induced motility in cells is known to be
mediated by a number of key pathways, including Akt and
PI3K pathways. The present study has shown that Akt is
probably more actively involved in the action as the small
inhibitor significantly blocked the action of HGFL/MSP in
both PC3 control and PC3 TGase-4exp cells.
The observations reported here have important implications
to prostate cancer. Over-expression of HGF-L/MSP and its
receptor RON have been reported in a few human solid
tumours, including pancreatic cancer, breast cancer, thyroid
and lung cancer. No large scale study is presently available
with regard to the expression pattern of the cytokine and
receptor in prostate cancer. In a recent study with small number
of prostate tumours (n=40), 10% of the prostate tumours were
found to over-express the RON protein. Here, the limited
information has shown the presence of RON in prostate cancer
cell lines that can be activated by HGF-L/MSP and staining of
RON in prostate epithelial cells and cancer cells. Clearly, a
large scale study is necessary in order to establish the expres-
sion pattern and relationship with tumour development and
progression in prostate cancer.
In conclusion, TGase-4 in prostate cancer cells is co-
localised with the HGF-L/MSP receptor RON. When over-
expressed, TGase-4 prostate cancer cells showed an enhanced
response to HGF-L/MSP as demonstrated by their increased
cell motility. This response appears to be Akt-dependent.
These observations suggest that: i) TGase-4 and HGFL/MSP
may have a synergistic effect toward initiating the aggressive
behaviour of prostate cancer cells and ii) targeting both RON
and TGase-4 may be a plausible approach for therapeutic
intervention in prostate cancer.
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